

National Survey of Precision Medicine in Cancer Treatment



This survey is about genomic testing for cancer treatment, also known as precision or personalized medicine. You are one of 3,000 oncologists in the United States randomly sampled to take part in this important research. The survey should take about 20 minutes to complete.

The survey is sponsored by the National Cancer Institute, the National Human Genome Research Institute and the American Cancer Society to help better understand current and potential use of genomic tests, including single gene tests and multi-marker tumor panels. The findings from the survey will also be used to identify future research needs and to help inform the development of educational materials for providers and patients.

NCI is being assisted by RTI International in fielding this survey. The survey is voluntary, but it is important to the success of the study that everyone chosen takes part.

The information you provide will be kept private and your name or any other information that could identify you will not be associated directly with the results.

If you would like further information about the survey please contact us at 1-866-590-7469 or email: PrecisionMedicine@rti.org.

If you would like further information about how RTI ensures that this NCI survey is carried out ethically and protects respondent privacy, you can contact our ethics review board directly at opre@rti.org.

We thank you in advance for your time and your valuable contribution to this research.

OMB No: 0925-XXXX
Expires: XX/XX/20XX

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Rights of study participants are protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing from the study at any time. Refusal to participate will not affect your benefits in any way. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all study participants and reported as summaries. You are being contacted by email to complete this instrument so that we can understand how genomic testing results are used to inform cancer treatment.

Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-XXXX). Do not return the completed form to this address.

Next

Please navigate the survey by using the "Back" and "Next" buttons below. Using your browser's back button, may disrupt the survey.

Back

Next

2%



This survey is about genomic testing for cancer treatment, also known as precision or personalized medicine. It is intended for oncologists who have treated or evaluated patients with cancer, including hematologic malignancies and solid tumors. Have you treated or evaluated any patients with any type of cancer in the past 12 months?

- I have treated or evaluated cancer patients in the past 12 months
 - I have **NOT** treated or evaluated cancer patients in the past 12 months
-

Back

Next

3%



Section A: Your Patient Population

This questionnaire focuses on treatment and evaluation of patients with cancer, including hematologic malignancies and solid tumors.

A1. On average, how many unique patients do you see for evaluation or treatment each month? Your best estimate is fine.

Total unique patients per month

Of those, how many are cancer patients? Your best estimate is fine.

Unique cancer patients per month

Back

Next

5%



A2. On average, how many unique patients with the following cancers do you see for evaluation or treatment each month?

	None	1-10 patients per month	11-25 patients per month	26-50 patients per month	51+ patients per month
Breast cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Colorectal cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Glioma	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Gynecological cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hematological cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Kidney cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lung cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Melanoma	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Stomach (Gastric) cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other Solid Tumor	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

7%



A3. By newly diagnosed, we mean patients who were diagnosed with cancer for the first time and have not yet started treatment. On average, how many **newly diagnosed** cancer patients do you see for evaluation or treatment **each month**? Your best estimate is fine.

Newly diagnosed cancer patients

Back

Next

9%

A4. By metastatic, we mean cancer that has spread to other parts of the body. By recurrent, we mean cancer that has come back after a period of time during which the cancer could not be detected. On average, how many patients with **metastatic or recurrent cancers** do you see for evaluation or treatment **each month**? Your best estimate is fine.

Metastatic or recurrent cancer patients

Back

Next

10%

Section B: Multi-Marker Tumor Panel Testing

Section B focuses on your use of and experience with **multi-marker tumor panels** such as FoundationOne or Target Now. For this survey, a multi-marker tumor panel is defined as a test that allows multiple genes to be assessed for mutations, alterations, or expression that may provide clinically actionable information

We will ask about single gene tests (tests for individual genes or chromosomal mutations) in Section C.

Back

Next

12%

A horizontal progress bar with a blue segment on the left and a grey segment on the right. The blue segment is labeled '12%'.

B1a. How many of your cancer patients received the following multi-marker tumor panels within the **past 12 months**? Please include tests that were ordered by other physicians and tests performed by pathology.

	Not familiar with this test	Familiar with this test, but not used in the past 12 months	1-10 patients in the past 12 months	11-25 patients in the past 12 months	26+ patients in the past 12 months
BioSpeciFix (Precision Therapeutics)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
DecisionDX (Castle DX)	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
FoundationOne (Foundation Medicine)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
FoundationOne Heme (Foundation Medicine)	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Mammaprint (Agendia)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
OncoPlex (Diagnostics)	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Oncotype DX Breast (Genomic Health)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Oncotype DX Colon (Genomic Health)	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>

Back

Next

14%



B1b. How many of your cancer patients received the following multi-marker tumor panels within the **past 12 months**? Please include tests that were ordered by other physicians and tests performed by pathology.

	Not familiar with this test	Familiar with this test, but not used in the past 12 months	1-10 patients in the past 12 months	11-25 patients in the past 12 months	26+ patients in the past 12 months
Prosigna (NanoString Technologies)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Response DX (Response Genetics)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Solid Tumor Mutation Panel (ARUP)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Suraseq 7500 (Asuragen)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Target Now (Caris Molecular Intelligence)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In-house tumor panel	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

16%

B1c. Have your cancer patients received any other multi-marker tumor panels in the past 12 months?

- Yes
- No

Back

Next

17%

B1d. Please list all other multi-marker tumor panels your patients have received in the past 12 months.

Characters used: 0 out of 300.

Back

Next

21%



The next section asks additional questions about multi-marker tumor panels. For these questions please **exclude** Oncotype DX for breast.

Back

Next

21%



B2. In the **past 12 months**, for what percentage of your patients receiving multi-marker tumor panels, **excluding** Oncotype DX for breast, did you use the results to guide patient care decisions? Your best estimate is fine.

 %

Back

Next

22%

B3. In the **past 12 months**, how often did you use the results from multi-marker tumor panels, **excluding** Oncotype DX for breast, to guide care decisions when treating the following types of patients?

	Did not see these patients	Never	Rarely	Sometimes	Often	Always or Almost Always
Patients with an initial diagnosis of cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patients with advanced refractory disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patients with rare cancers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patients with cancers of unknown origins	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patients for whom there is an FDA-approved therapy associated with a companion diagnostic	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patients on specific clinical trials that have a companion molecular test	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

26%

B4. In the **past 12 months**, have you used the results from multi-marker tumor panels, **excluding** Oncotype DX for breast, for the following purposes:

	Yes	No
To guide the use of FDA-approved drugs	<input type="radio"/>	<input type="radio"/>
To help decide whether to use FDA-approved drugs for an off-label use	<input type="radio"/>	<input type="radio"/>
To provide diagnostic information	<input type="radio"/>	<input type="radio"/>
To provide prognostic information	<input type="radio"/>	<input type="radio"/>
To determine patient eligibility for clinical trials	<input type="radio"/>	<input type="radio"/>
Other (Please, specify):	<input type="radio"/>	<input type="radio"/>

Back

Next

28%

B5a. In the **past 12 months**, when you used the results of multi-marker tumor panels for your patients, **excluding** Oncotype DX for breast, how often did you experience the following?

	Never	Rarely	Sometimes	Often	Always or Almost Always
The test results assisted in making a diagnosis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The test results helped to inform my treatment recommendations	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The test results provided important information on prognosis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The test results were helpful to patients or their families in understanding their disease and making decisions	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

29%



B5b. In the **past 12 months**, when you used the results of multi-marker tumor panels for your patients, **excluding** Oncotype DX for breast, how often did you experience the following?

	Never	Rarely	Sometimes	Often	Always or Almost Always
The test results were conclusive, but not actionable	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The test results were inconclusive/indeterminate	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
The test results were difficult to interpret	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The recommended drugs based on test results were not covered by insurance	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
The test results confirmed eligibility for a clinical trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

31%



B6. In the **past 12 months**, when you ordered or requested multi-marker tumor panel testing, **excluding** Oncotype DX for breast, for your patients in the past 12 months, how often did you experience the following?

	Never	Rarely	Sometimes	Often	Always or Almost Always	Don't Know
At least some costs were covered by insurance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Inadequate reimbursement was paid to physician or hospital	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Uncertainty as to whether the test was indicated for patient's clinical situation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Long wait to receive tests results that caused a delay in making patient care decisions	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patient reluctance due to concern that hereditary genetic abnormalities might be found	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

33%



B7. In the **past 12 months**, how important was each of the following factors in your decision to use multi-marker tumor panels to make **treatment decisions** for your cancer patients?

	Not at all important	A little important	Somewhat important	Very Important
Availability of guidelines (e.g., ASCO, NCCN) for the test	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Your familiarity with guidelines (e.g., ASCO, NCCN) for the test	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Your formal education or training (e.g., residency/fellowship, CME, lecture or symposia) on the test	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Past experience with the test	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
FDA approval of the test for the patient population being tested	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Information about the test from test suppliers or company representatives	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>

Back

Next

34%



B8. In the **past 12 months**, how important was each of the following factors in your decision to use multi-marker tumor panels to make treatment decisions for your cancer patients?

	Not Applicable	Not at all important	A little important	Somewhat important	Very Important
Performance characteristic of the test (e.g., positive predictive value, sensitivity, specificity)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Prevalence of genetic alterations among patients with a specific type of cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ability of the test to predict clinical benefit of specific treatments	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ability of the test to predict toxicity of specific treatments	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ability of the test to provide prognostic information	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ability of the test to provide diagnostic information (e.g. for a cancer of unknown primary)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

36%

B9. In the **past 12 months**, how important was each of the following factors in your decision to use multi-marker tumor panels to make treatment decisions for your cancer patients?

	Not at all important	A little important	Somewhat important	Very Important
Patient or family preferences	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Test is covered by patient's insurance	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Treatment is covered by patient's insurance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patient out-of-pocket expenses for testing	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Patient out of pocket expenses for treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

38%



B10. In the **past 12 months**, how often, if at all, did you use the following practice guidelines or recommendations for multi-marker tumor panels when making treatment decisions for cancer patients?

	I am not familiar with these guidelines	Never	Rarely	Sometimes	Often	Always or Almost always
American Society of Clinical Oncology (ASCO)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Blue Cross Blue Shield (BCBS) or the BCBS Technical Evaluation Center	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Evaluation of Genomic Applications in Practice and Prevention (EGAPP)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
National Comprehensive Cancer Network (NCCN)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

B10e. Please list any other practice guidelines or recommendations you have used in the past 12 months.

Characters used: 0 out of 300.

Back

Next

40%

B11. In the **past 12 months**, what percentage of your cancer patients initiated a discussion with you about multi-marker tumor panels? Please include when a family member or other caregiver asked on the patient's behalf. Your best estimate is fine.

 %

Back

Next

41%

B12a. The next question is about the times during the **past 12 months** when you decided **NOT** to order a multi-marker tumor panel for a cancer patient. When this occurred, how often was it for the following reasons?

	Never	Rarely	Sometimes	Often	Always or Almost Always
Multi-marker testing was not relevant for the patient	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Used tests for individual genes, rather than multi-marker tumor panels	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Not enough evidence of utility	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Multi-marker panels were not available in my practice	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Test was not covered by patient's insurance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Out-of-pocket costs for tests were too expensive for the patient	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Provider reimbursement for tests was insufficient	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

41%

B12b. This question is also about the times during the **past 12 months** when you decided NOT to order a multi-marker tumor panel for a cancer patient. When this occurred, how often was it for the following reasons?

	Never	Rarely	Sometimes	Often	Always or Almost Always
Lack of personnel or resources to interpret test results	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Uncertainty regarding informed consent procedures	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Difficulty obtaining sufficient tissue for testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Insufficient time to order tests or review results	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patient's or patient's family preferences	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

43%



B13. In the **past 12 months**, how often, if at all, were the following barriers to involving your cancer patients or their families in the decision-making process for multi-marker tumor panels?

	Never	Rarely	Sometimes	Often	Always or Almost Always
Difficulty getting patient/family to understand the purpose of the test	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Difficulty getting patient/family to understand treatment options	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Lack of educational materials to share with patient/family	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Insufficient time to discuss testing or treatment options with patient/family	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Patient/family resistant to testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of patient/family interest in testing	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>

Back

Next

45%

B14. In the **past 12 months**, did you rely on any of the following to learn about using a new multi-marker tumor panel for cancer patients?

	Yes	No
Informal networks (e.g., colleagues)	<input type="radio"/>	<input type="radio"/>
National or international experts	<input type="radio"/>	<input type="radio"/>
Testing laboratories or pathologists	<input type="radio"/>	<input type="radio"/>
Test manufacturers or drug company representatives or websites	<input type="radio"/>	<input type="radio"/>
FDA package inserts	<input type="radio"/>	<input type="radio"/>
Scientific meetings or conferences	<input type="radio"/>	<input type="radio"/>
Peer-reviewed medical literature	<input type="radio"/>	<input type="radio"/>
Medical professional societies such as ASCO or NCCN	<input type="radio"/>	<input type="radio"/>
Government (e.g., NIH) websites or materials	<input type="radio"/>	<input type="radio"/>
Foundation or cancer patient advocacy websites or materials	<input type="radio"/>	<input type="radio"/>
Evidence-based, synthesized website (e.g., UpToDate)	<input type="radio"/>	<input type="radio"/>
Other (Please, specify):	<input type="radio"/>	<input type="radio"/>

Back

Next

47%

B15. In the **past 12 months**, did you refer any of your cancer patients to another location or provider for a multi-marker tumor panel?

- Yes
- No

Back

Next

48%

B16. In the **past 12 months**, did you refer any of your cancer patients to any of the following for a multi-marker tumor panel?

	Yes	No
Comprehensive Cancer Center	<input type="radio"/>	<input type="radio"/>
Academic medical center	<input type="radio"/>	<input type="radio"/>
Oncologist outside your practice	<input type="radio"/>	<input type="radio"/>
Clinical trial	<input type="radio"/>	<input type="radio"/>
Other (Please, specify):	<input type="radio"/>	<input type="radio"/>

Back

Next

50%



B17. In the **past 12 months**, what percentage of your cancer patients presented with results from a commercially available multi-marker tumor test that was not ordered through you or your practice?

- None
- <10%
- 11%-25%
- 26%-50%
- 51%-80%
- >80%

Back

Next

52%

A horizontal progress bar with a blue segment on the left and a grey segment on the right. The blue segment is labeled '52%'.

Section C: Genomic Testing

The previous questions asked about multi-marker tumor panels. This section asks about **both multi-marker tumor panel testing and single gene tests** (tests for individual genes or chromosomal mutations).

C1. In the **past 12 months**, have you used results from genomic tests (either multi-marker tumor panels or single gene tests) for any of the following individual genes or chromosomal mutations to make treatment decisions for your cancer patients?

Stomach Cancer	Yes	No
KIT mutation	<input type="radio"/>	<input type="radio"/>
HER2/neu amplification	<input checked="" type="radio"/>	<input type="radio"/>

Colon Cancer	Yes	No
BRAF mutation	<input type="radio"/>	<input type="radio"/>
KRAS mutation	<input checked="" type="radio"/>	<input type="radio"/>
Microsatellite instability (MSI)	<input type="radio"/>	<input type="radio"/>

Back

Next

53%



C1. In the **past 12 months**, have you used results from genomic tests (either multi-marker tumor panels or single gene tests) for any of the following individual genes or chromosomal mutations to make treatment decisions for your cancer patients?

Hematologic Malignancy	Yes	No
BCL2-IGH translocation	<input type="radio"/>	<input type="radio"/>
BCR-ABL translocation	<input type="radio"/>	<input type="radio"/>
KIT mutation	<input type="radio"/>	<input type="radio"/>
FLT3 mutation	<input type="radio"/>	<input type="radio"/>
IGH rearrangement	<input type="radio"/>	<input type="radio"/>
JAK2 mutation	<input type="radio"/>	<input type="radio"/>
MPL mutation	<input type="radio"/>	<input type="radio"/>
PML-RARA translocation	<input type="radio"/>	<input type="radio"/>
TRG rearrangement	<input type="radio"/>	<input type="radio"/>

Back

Next

55%



C1. In the past 12 months, have you used results from genomic tests (either multi-marker tumor panels or single gene tests) for any of the following individual genes or chromosomal mutations to make treatment decisions for your cancer patients?

Glioma	Yes	No
1p/19q deletion	<input type="radio"/>	<input type="radio"/>
IDH mutation	<input checked="" type="radio"/>	<input type="radio"/>
MGMT mutation	<input type="radio"/>	<input type="radio"/>

Melanoma	Yes	No
r. BRAF mutation	<input type="radio"/>	<input type="radio"/>

Back

Next

57%



C1. In the **past 12 months**, have you used results from genomic tests (either multi-marker tumor panels or single gene tests) for any of the following individual genes or chromosomal mutations to make treatment decisions for your cancer patients?

Lung Cancer	Yes	No
EGFR mutation	<input type="radio"/>	<input type="radio"/>
ERCC1 mutation	<input type="radio"/>	<input type="radio"/>
EML4-ALK translocation	<input type="radio"/>	<input type="radio"/>
KRAS mutation	<input type="radio"/>	<input type="radio"/>
ROS1 mutation	<input type="radio"/>	<input type="radio"/>

Breast Cancer	Yes	No
HER2/neu amplification	<input type="radio"/>	<input type="radio"/>

Other Genes Or Mutations	Yes	No
Other genes or mutations	<input type="radio"/>	<input type="radio"/>

[Back](#) [Next](#)



C2. In the **past 12 months**, when you or your staff discussed any form of genomic testing with your cancer patients or their families, how often did you discuss the likely costs of the testing and related treatment?

- Never
- Rarely
- Sometimes
- Often
- Always or almost always
- Not discussed in past 12 months

Back

Next

60%

C3. For each of the following tests, how confident are you in your ability to determine whether the test is **clinically appropriate** for a patient?

	Not at all confident	A little confident	Moderately confident	Very confident	Extremely confident
Commercially available multi-marker tumor panels (e.g., FoundationOne, Oncotype DX)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In-house multi-marker tumor panels	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Whole genome sequencing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tests for individual genes or chromosomal mutations (e.g., KRAS for colorectal cancer)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Whole exome sequencing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

62%

C4. For each of the following tests, how confident are you in your ability to explain the testing purpose and procedures to a patient?

	Not at all confident	A little confident	Moderately confident	Very confident	Extremely confident
Commercially available multi-marker tumor panels (e.g., FoundationOne, Oncotype DX)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In-house multi-marker tumor panels	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
Whole genome sequencing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tests for individual genes or chromosomal mutations (e.g., KRAS for colorectal cancer)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Whole exome sequencing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

64%



C5. For each of the following tests, how confident are you in your ability to use the results of the test to **guide decisions** about patient treatment and management?

	Not at all confident	A little confident	Moderately confident	Very confident	Extremely confident
Commercially available multi-marker tumor panels (e.g., FoundationOne, Oncotype DX)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
In-house multi-marker tumor panels	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Whole genome sequencing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tests for individual genes or chromosomal mutations (e.g., KRAS for colorectal cancer)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Whole exome sequencing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

66%



Section D: Breast Cancer

The next few questions are about breast cancer patients

D1. In the past 12 months, have you seen any **breast cancer** patients for evaluation or treatment?

- Yes
- No

Back

Next

67%

D2. A female patient presents with ER+, HER2- breast cancer with a high recurrence score (≥ 26) from the OncotypeDX Breast Cancer Assay. Which of the following factors would be important to you in deciding whether to recommend chemotherapy for this patient?

	Yes	No
Age ≥ 75	<input type="radio"/>	<input type="radio"/>
Presence of cardiomyopathy	<input type="radio"/>	<input type="radio"/>
Black or African American race	<input type="radio"/>	<input type="radio"/>
Patient's inability to pay out-of-pocket expenses	<input type="radio"/>	<input type="radio"/>
Patient's preferences not to receive chemotherapy	<input type="radio"/>	<input type="radio"/>
Other (Please specify):	<input type="radio"/>	<input type="radio"/>

Back

Next

69%

D3. A female patient presents with ER+, HER2- breast cancer with a low recurrence score (<18) on the OncotypeDX Breast Cancer Assay. Which of the following factors would be important to you in deciding whether to recommend chemotherapy for the patient?

	Yes	No
Age ≤ 45	<input type="radio"/>	<input type="radio"/>
No co-morbidities, otherwise healthy patient	<input type="radio"/>	<input type="radio"/>
Black or African American race	<input type="radio"/>	<input type="radio"/>
Patient ability to pay out-of-pocket cost	<input type="radio"/>	<input type="radio"/>
Patient's amenability to chemotherapy	<input type="radio"/>	<input type="radio"/>
Other (Please specify):	<input type="radio"/>	<input type="radio"/>

Back

Next

71%



Section E: Lung Cancer

The next few questions are about lung cancer patients

E1. In the **past 12 months**, have you seen any **lung cancer** patients for evaluation or treatment?

- Yes
- No

Back

Next

72%

E2. A 57 year-old man who presented with increased dyspnea on exertion and is diagnosed with Stage IV non-small cell lung cancer with adenocarcinoma histology. His relevant medical history includes 35 pack-years of smoking; he quit 5 years ago. He has an excellent performance status (ECOG PS 1). For which of the following mutations would you consider requesting or ordering a genomic test, and when would you order the test?

	All such patients are tested at time of diagnosis (reflex testing)	I would test THIS patient at time of diagnosis	I would wait until the time of progression to consider	I would not order the test for THIS patient
<i>EGFR</i> Mutation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<i>ALK</i> rearrangement	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<i>ROS1</i> rearrangement	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<i>KRAS</i> Mutation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<i>RRM1</i> Expression	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<i>ERCC1</i> Expression	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<i>BRAF</i> Mutation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Next generation Sequencing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

74%

Section F: Colorectal Cancer

The next few questions are about colon cancer patients

F1. In the past 12 months, have you used multi-marker tumor testing to guide care decisions for colorectal cancer patients?

- Yes
- No

Back

Next

76%

F2. For each of the following clinical scenarios, at what point in time, if at all, would you request a multi-marker tumor test for your colorectal cancer patients?

	All such patients are tested at time of diagnosis (reflex testing)	I would test THIS patient at time of diagnosis	I would wait until the time of progression to consider	I would not order the test for THIS patient
A newly diagnosed 74-year-old man with Stage IV KRAS mutant colon cancer	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
A 35-year-old woman with metastatic colon cancer recently progressed on first line therapy and found to have a BRAF mutation	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>
A 65-year-old woman with Stage II disease with high risk features of perforation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
A 45-year-old woman with Lynch Syndrome presenting with Stage III disease receiving adjuvant therapy with FOLFOX	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>

Back

Next

78%

Section G: About You and Your Practice

The next set of questions will help us to better understand you and your primary medical practice. By primary medical practice we mean the site where you see most of your cancer patients.

G1. Is your primary practice a...

- Solo practice
- Single specialty group
- Multi-specialty group

Other (Please specify):

G2. Including yourself, how many full- and part-time physicians are in your primary practice?

Number

Back

Next

79%



G3. How would you characterize your primary practice?

- Urban
- Suburban
- Rural

G4. Does your primary practice provide care for patients living in rural areas as part of an outreach or visiting clinician arrangement?

- Yes
- No

Back

Next

81%

G5. Does your primary practice have the following genomic testing services?

	Yes	No	Don't know
On-site pathology	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Contracts with outside testing laboratories to perform tests not available on-site	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
On-site genetic counselors	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Internal policies or protocols for use of genomic and biomarker testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
An EMR that alerts providers when a genomic test is recommended for a particular patient or before ordering a particular drug	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Back

Next

83%

G6. In 2014, what percentage of your patients were Medicare, Medicaid, and self-pay/uninsured?

% Medicare

% Medicaid

% Self-pay or uninsured

Back

Next

84%



G7. In which of the following practice settings do you see patients for treatment or evaluation? *(Please check all that apply)*

- Academic medical center or medical school
- Medical center not affiliated with a medical school
- Community hospital
- Office-based
- Integrated healthcare delivery system
- Other (Please specify):

G8. Is your primary practice affiliated with an academic institution such as a medical school or teaching hospital? Do not include where your practice only has admissions privileges.

- Yes
- No

Back

Next

86% 

Lastly, we have just a few more questions about you and your background.

G9. What is your primary specialty? Please think about the one specialty in which you spend most of your time.

- Medical oncology
- Hematology
- Hematology/oncology
- Pediatric hematology/oncology
- Other (Please specify):

Back

Next

88%

G10. For how many years have you been practicing in your primary specialty, including fellowship? Please specify in whole years, rounding up to the nearest year.

Years

G11. Do you hold a faculty appointment or do you have a teaching assignment at a medical school or hospital?

- Yes
- No

Back

Next

90%

G12. During a typical month, approximately what percentage of your professional time do you spend in the following activities?

<input type="text"/>	% Providing patient care
<input type="text"/>	% Research
<input type="text"/>	% Teaching
<input type="text"/>	% Administration

Back

Next

91%

G13. Have you received any formal training (e.g. instruction during residency/fellowship, professional lectures or seminars, symposiums, conferences, CMEs) in use of **genomic testing**?

- Yes
- No

G14. Which of these best describes your ethnicity? (*Choose one.*)

- Hispanic or Latino
- Not Hispanic or Non-Latino

Back

Next

93%

G15. Which of these best describes your race? (*Choose one or more.*)

- American Indian or Alaska Native
- Asian
- Black or African-American
- Native Hawaiian or other Pacific Islander
- White

Back

Next

95%

If you have any additional thoughts about any of the survey topics or the survey itself, please share them here:

Characters used: 0 out of 1000.

Back

Submit

98%

Thank you

Thank you for taking the time to complete this questionnaire. Your contribution is valuable to us. The information you have provided will be kept private and any information that could identify you will not be associated directly with the results.

If you have questions about this survey, please email us at PrecisionMedicine@rti.org or call us toll-free at 1-866-590-7469.

100%



 This question is required. Please provide a response to continue.

This survey is about genomic testing for cancer treatment, also known as precision or personalized medicine. It is intended for oncologists who have treated or evaluated patients with cancer, including hematologic malignancies and solid tumors. Have you treated or evaluated any patients with any type of cancer in the past 12 months?

- I have treated or evaluated cancer patients in the past 12 months
- I have **NOT** treated or evaluated cancer patients in the past 12 months

Back

Next

3%



Thank you for taking time to complete this survey.

Unfortunately, you are not eligible to participate in this study at this time.

If you would like further information about the survey please contact us at 1-866-590-7469 or email: PrecisionMedicine@rti.org.